ReviewFrontiers in oncology2022
Financial toxicity in lung cancer.
Review in Frontiers in oncology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 1 synthesis or guideline pooled it, 22 citations in OpenAlex.
- Financial toxicity among patients with lung cancer: a systematic review and meta-analysis.Frontiers in public health · 2026Pooled it
- Longitudinal Associations Between Financial Toxicity and Health-Related Quality of Life for Patients With Cancer.JCO oncology practice · 2026Article
- Association of medicaid expansion with lung cancer-specific and overall mortality: A difference-in-differences analysis.PloS one · 2026Article
- Impact of Medicaid Expansion on Lung Cancer Survival Outcomes: A Difference-in-Differences Analysis.medRxiv : the preprint server for health sciences · 2025Article
- Utility of Germline, Somatic and ctDNA Testing in Adults With Cancer.Cancer medicine · 2025Review
- Validation of the Chinese version of the financial toxicity scale in patients with wet age-related macular degeneration.Journal of patient-reported outcomes · 2025Article
- Potential profile analysis of financial toxicity and its related factors among lung cancer patients.BMC cancer · 2025Article
- Proceedings of the 1st biannual bridging the gaps in lung cancer conference.The oncologist · 2025Article
- Existing Health Inequities in the Treatment of Advanced and Metastatic Cancers.Current oncology reports · 2024Review
- Hemin Promotes Higher Effectiveness of Aminolevulinic-Photodynamic Therapy (ALA-PDT) in A549 Lung Cancer Cell Line by Interrupting ABCG2 Expression.Medical sciences (Basel, Switzerland) · 2024Article
- Factors influencing economic toxicity and coping strategies in lung cancer patients: A scoping review.Heliyon · 2024Article
- Trajectories of depression and predictors in lung cancer patients undergoing chemotherapy: growth mixture model.BMC psychiatry · 2024Article
- The impact of humanitarian aid on financial toxicity among cancer patients in Northwest Syria.BMC health services research · 2024Article
- Social determinants of health and lung cancer surgery: a qualitative study.Frontiers in public health · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 4 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
In the United States, lung cancer is the third most common cancer and the overall leading cause of cancer death. Due to advances in immunotherapy and targeted therapy, 5-year survival is increasing. The growing population of patients with lung cancer and cancer survivors highlights the importance of comprehensive cancer care, including recognizing and addressing financial toxicity. Financial toxicity is a term used to contextualize the negative effects of the costs of cancer treatment in terms of patient quality of life. The American Society of Clinical Oncology (ASCO) Value Framework places emphasis on high-value care as it evaluates cancer treatments "based on clinical benefit, side effects, and improvements in patient symptoms or quality of life in the context of cost". Prior studies have shown that risk factors for financial toxicity in patients with lung cancer include lower household income or savings, inability to afford basic necessities, higher than anticipated out of pocket expenses, and taking sick leave. Among lung cancer survivors, patients experience increased unemployment and lower wages compared to the general population underscoring the lasting effects of financial toxicity. Financial toxicity is associated with increased psychosocial distress and decreased quality of life, and bankruptcy is an independent predictor of mortality in patients with cancer. Despite the negative implications of financial toxicity on patients, standardized screening practices and evidence-based interventions are lacking. The "COmphrensive Score for financial Toxicity (COST)" tool has been validated for assessing financial toxicity with correlation with health-related quality of life. Further research is needed to understand the utility of incorporating routine screening for financial toxicity into clinical practice and the efficacy of interventions. Understanding the relationship between financial toxicity and quality of life and survival is critical to providing high-value cancer care and survivorship care.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.